3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Lung Neoplasms
9
Hematopoietic and Lymphatic System Neoplasm
7
Prostatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Hematopoietic and Lymphoid System Neoplasm
3
Hematologic Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Malignant Solid Neoplasm
2
Head and Neck Carcinoma
2
Fallopian Tube Neoplasms
2
Vulvar Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Ureteral Neoplasms
1
Tonsillar Neoplasms
1
Tongue Neoplasms
1
Teratoma
1
Stomatitis
1
Spondylitis, Ankylosing
1
Psoriasis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Interventions
Oxaliplatin
13
Bevacizumab
11
Capecitabine
10
Fluorouracil
8
Blood Specimen Collection
8
Leucovorin
7
Cetuximab
7
Folfox protocol
6
pembrolizumab
5
Drug Therapy
5
trifluridine tipiracil drug combination
4
dostarlimab
4
Nivolumab
4
Irinotecan
4
HMPL-013
4
fludarabine
3
XELOX
3
Specimen Handling
3
IFL protocol
3
Cyclophosphamide
3
Biopsy
3
toripalimab
2
tislelizumab
2
tipiracil
2
regorafenib
2
pertuzumab
2
envafolimab
2
encorafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colonic Neoplasms
×
Practice Guidelines as Topic
×
Clear all
NCT06563388
2026-02-04
ID-COMET
Roswell Park Cancer Institute
Phase 3
Recruiting
800 enrolled